AngioDynamics, Inc. announced that as a result of lower than anticipated AngioVac sales, management now expects the Company's fiscal year 2023 net sales to be in the range of $338 million to $342 million, a decrease from its prior guidance of $342 million to $348 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.81 USD | +0.52% | -7.19% | -25.89% |
04-08 | North American Morning Briefing : Inflation Data, -2- | DJ |
04-05 | Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.89% | 233M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- Angiodynamics, Inc. Revised Revenue Guidance for the Fiscal 2023